PYXAX exists because the research compound market has a trust problem, not a price problem. Here is the standard we are building around: documented sourcing, independent testing, lot-level COAs, and clear language before any batch enters the launch catalog.
In the research peptide space, the compound itself is rarely what separates one supplier from another. What separates them is everything downstream — how it's handled, whether it's tested, and whether anyone can prove what's actually in the vial.
PYXAX was built around one idea — verification isn't a marketing checkbox, it's the product. Every compound that reaches Core Stock status should have a documented chain from sourcing to third-party lab analysis to a published Certificate of Analysis. If we cannot verify it, we will not list it as verified.
This page exists so you don't have to take our word for any of that. Below is the operating standard, the language we intend to use around Certificates of Analysis, and what each tier of the launch catalog will mean.
This sequence is the planned standard for every compound batch before it is listed as Core Stock. Request Batch and Exclusive Access compounds are intended to follow the same verification pathway once a batch is confirmed.
Each compound is intended to be sourced from a vetted supplier and assigned an internal batch number at receipt. Every vial in that batch should trace back to a single production lot.
A representative vial from the batch is intended to be sent to an independent third-party laboratory for identity and purity testing. This sample is not sold or released into inventory.
The lab may run HPLC, LC-MS, or another appropriate analytical method against the expected compound profile. Results should return as a formal lab report tied to the batch number.
If the batch clears our minimum purity threshold, we publish a lot-level Certificate of Analysis — viewable before listing — showing the test method, result, and date.
Only after a COA is published does a batch move to Core Stock and become available at launch. Batches that don't clear threshold won't be listed — at any tier.
When a compound is available in multiple dosage strengths from the same production lot, we test one representative sample from that lot rather than testing every individual dosage separately. This is standard practice in lot-based quality control — and we want to be precise about what it does and doesn't mean.
That's the language we intend to use on our Certificates of Analysis, and it's the language we intend to use anywhere we describe testing. We will never describe a result as "every dosage individually tested" unless that is literally true for that listing — because it usually isn't, and claiming otherwise would misrepresent what the COA actually covers.
If you have questions about how a specific COA maps to a specific product you're considering, the batch ID on the product page should correspond directly to the batch ID on the published Certificate of Analysis. The goal is to keep the source document one click away.
Testing is one part of the picture. These are the standards PYXAX is being built around for sourcing, storage, and handling across the launch catalog.
PYXAX is designed around a small, qualified supplier network with documented lot numbers and batch records. The goal is to avoid opportunistic sourcing from marketplaces with no clear chain of custody.
The launch model is designed around disciplined storage for lyophilized compounds from receipt through fulfillment. Storage notes and handling windows should be published on product pages based on each compound's known stability profile.
Fulfillment is being designed around temperature-appropriate packaging with the relevant Certificate of Analysis reference included when available. Outer packaging is intended to remain discreet and non-promotional.
Not every compound PYXAX may source will sit in inventory — and we'd rather tell you that plainly than imply otherwise. Every listing falls into exactly one of these three categories.
Planned for batches that are in hand, verified, and COA-published before launch release. These are intended to ship from confirmed inventory once available.
Planned for compounds available through a supplier network but not held as standing inventory. Interest signals help determine whether PYXAX should source, test, and release a batch.
Planned for less common research compounds that may be evaluated by request. PYXAX may follow up directly to confirm sourcing feasibility and timeline.